Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00340847 · ClinicalTrials.gov registry record
Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 500
- Enrollment target
NCT00340847: Completed study, sponsored by National Cancer Institute (NCI).
NCT00340847 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00340847 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
The proposed research intends to construct a set of tissue microarrays containing different types of normal and lung cancer tissues for the study of genes associated with lung cancer. Thus far we have generated a lung cancer tissue arrayusing paraffin embedded archival tissues from 300 lung turmors tissues and 100 adjacent normal tissues. Four- micrometer thickness sections have been cut from the tissue array and were used to survey gene expression status in arrayed tumors using immunohistochemistry methody. We are currently performing IHC studies ot 1) determine protein expression and its correlation with gene expression patterms ovserved using cDNA arrays. 2) Analyze protein expression in the chromosome remodeling pathyway in non-small cell lung cancer. And 3) determine the association of gene expression with lung tumor stage and clinical outcome. The current protocol is needed to complete the above studies and for the production of neuroendocrine tumors.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2001-08-09 |
| Est. Completion | 2010-05-19 |
What the finished NCT00340847 record still lists
NCT00340847 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00340847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00340847 about?
NCT00340847 is a clinical study titled "Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer". The proposed research intends to construct a set of tissue microarrays containing different types of normal and lung cancer tissues for the study of genes associated with lung cancer. Thus far we have generated a lung cancer tissue arrayusing paraffin embedded archival tissues from 300 lung turmors ...
What is the current status of trial NCT00340847?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2001-08-09. Estimated completion is 2010-05-19.
Who is sponsoring clinical trial NCT00340847?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI